Loading stock data…
GERN
$1.58+0.04 (+2.60%)
Market ClosedLast close May 1
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Geron Corporation in the Healthcare sector is trading at $1.58. The stock is currently 21% below its 52-week high of $2.01, remaining 12.9% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why GERN maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.58
Potential Upside
5%
Whystock Fair Value$1.66
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$3.40+115.2%
Range$1.00 – $5.00
Fundamentals
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$993.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.12%
Volume
Today's trading volume
9.03M
Recent News
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer
Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal executive, Williams joins the commercial-stage biopharma firm from Vanda Pharmaceuticals, where he served as Senior Vice President and General […]
Geron Adds Chief Legal Officer As Equity Ties To Execution Risk
Geron (NasdaqGS:GERN) has appointed Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams received an equity award as an inducement to join the company, reflecting the importance of his role. The appointment adds legal and compliance leadership experience from commercial stage biopharmaceutical companies to Geron's executive team. Geron, trading at $1.77, has seen its shares return 34.1% year to date and 41.6% over the past year, while the 3...
Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf
Geron (NASDAQ:GERN) executives used a presentation at the Needham Healthcare Conference to outline the company’s early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamic
Geron Adds Biopharma Veterans As RYTELO Focus And Valuation Draw Attention
Geron (NasdaqGS:GERN) appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. Both executives bring extensive experience in commercial-stage biopharmaceuticals and product launches. The appointments come as Geron focuses on introducing and expanding its blood cancer treatment, RYTELO. Geron is a commercial-stage biopharmaceutical company focused on therapies for blood cancers, with RYTELO as its key product. Bringing in board members with a background in...
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference
Executives from Geron (NASDAQ:GERN) outlined their commercial priorities for RYTELO (imetelstat) and provided updates on the company’s pipeline and financial outlook during a discussion hosted by Barclays. Leadership says commercial plan is being refined as RYTELO enters second year Harout Semerjia